Mulmit

Spyre Therapeutics, Inc.Spyre Therapeutics, Inc.

SYRE Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-310-209,562,000-155,200,000
2024-12-310-208,566,000-208,018,000
2023-12-31886,000-242,303,000-338,790,00013.76
2022-12-312,329,000-84,781,000-83,815,000-24.86
2021-12-3118,739,000-65,649,000-65,801,000-25.02

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-07Albers Jeffrey W.5,000
2026-08-07Albers Jeffrey W.5,000
2026-08-07Albers Jeffrey W.8,000
2026-08-07Albers Jeffrey W.10,000
2026-08-07Albers Jeffrey W.5,000
2026-08-03Burrows Scott LChief Financial Officer7,500
2026-08-03Burrows Scott LChief Financial Officer5,100
2026-08-03Burrows Scott LChief Financial Officer2,300
2026-08-03Burrows Scott LChief Financial Officer100
2026-08-03Burrows Scott LChief Financial Officer7,500
2026-08-03Turtle CameronChief Executive Officer800
2026-08-03Turtle CameronChief Executive Officer7,157

8-K events

FiledItems
2026-08-25Regulation FD disclosure · Other events · Financial statements and exhibits
2026-08-04Results of operations · Financial statements and exhibits
2026-06-15Regulation FD disclosure · Other events · Financial statements and exhibits
2026-06-01Other events · Financial statements and exhibits
2026-05-29Officer or director change · Submission of matters to a vote · Financial statements and exhibits
2026-05-05Results of operations · Financial statements and exhibits
2026-04-16Entry into a material agreement · Financial statements and exhibits
2026-04-13Results of operations · Other events
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…